Ascendis Pharma (ASND) Tops Q2 EPS by 45c

Ascendis Pharma (NASDAQ: ASND) reported Q2 EPS of (EUR0.82), EUR0.45 better than the analyst estimate of (EUR1.27). Revenue for the quarter came in at EUR158.05 million versus the consensus estimate of EUR142.38 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• Trump on Iran: we're trying to work out a deal that's fair
• Varonis Said To Weigh Sale After Takeover Interest - Bloomberg
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance